Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests
Key Points
10,000 Common Stock shares were sold for a transaction value of $402,000 at an average price of around $40.24 per share on June 18, 2026.
The sale represented 38% of Halpin's direct Common Stock holdings, reducing his direct stake from 26,248 to 16,248 shares, though he also has options.
All shares were acquired via option exercise and disposed of in a single direct transaction; no indirect entities participated.
- 10 stocks we like better than Vericel ›
Michael Halpin, Chief Operating Officer of Vericel Corporation (NASDAQ:VCEL), reported the sale of 10,000 shares of Common Stock for a transaction value of approximately $402,000 on June 18, 2026, as disclosed in a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares traded (direct) | 10,000 |
| Transaction value | ~$402K |
| Post-transaction shares (direct) | 16,248 |
| Post-transaction value (direct ownership) | ~$652K |
Transaction value based on SEC Form 4 weighted average purchase price ($40.24); post-transaction value based on June 18, 2026 market close.
Key questions
- How does this transaction compare to Halpin's historical sale sizes?
The 10,000-share sale aligns with the range recorded over the past two years. - What is the impact on Halpin's overall equity exposure in Vericel?
While direct Common Stock holdings decreased to 16,248 shares, Halpin maintains 36,250 options outstanding, preserving a substantial economic interest that could be exercised for future share acquisition. - What was the structure and motivation of the transaction?
This sale consisted of an option exercise immediately followed by an open-market disposition. - Did the transaction occur at a premium or discount to recent market prices?
The weighted average sale price of around $40.24 per share closely tracked the market close of $40.10 on June 18, 2026, suggesting execution in line with prevailing market levels at the time of sale.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close 6/18/26) | $40.24 |
| Market capitalization | $2.36 billion |
| Revenue (TTM) | $292.09 million |
| Net income (TTM) | $21.46 million |
Company snapshot
- Vericel's core products include MACI, an autologous cellularized scaffold for knee cartilage repair, and Epicel, a permanent skin replacement for severe burns; NexoBrid, a biological eschar removal product, is in the registration phase.
- The company generates revenue through the commercialization of its proprietary cell-based therapies and related biologics, targeting critical needs in sports medicine and burn care.
- Primary customers are hospitals, burn centers, and orthopedic clinics in the United States, with a focus on patients requiring advanced regenerative treatments for cartilage damage or severe burns.
Vericel Corporation operates as a commercial-stage biopharmaceutical company specializing in advanced cell therapies for sports medicine and burn care. With a focused product portfolio and established distribution in the U.S. hospital and specialty clinic markets, the company leverages proprietary technologies to address unmet medical needs. Its strategy centers on expanding the adoption of its FDA-approved therapies and advancing new indications to strengthen its competitive position in regenerative medicine.
What this transaction means for investors
The sale here was conducted under a trading plan adopted at the end of last year, and with Halpin maintaining exposure to VCEL, it doesn’t seem to signal anything about Vericel's long-term outlook.
That comes as Vericel continues to build momentum operationally, even if its shares have been anything but steady. The stock has swung sharply over the past year and is up about 10% over that stretch. In the first quarter, Vericel reported record revenue of $68.4 million, up 30% year over year, while adjusted EBITDA nearly tripled to $9.6 million. The company also raised its full-year revenue guidance by $10 million to a range of $326 million to $336 million after strong growth across its MACI cartilage repair and burn care franchises.
President and CEO Nick Colangelo said the company delivered "outstanding financial and business results" and believes Vericel is positioned for another year of strong revenue and profit growth.
For long-term investors, routine option-related insider sales are generally less informative than execution. The bigger question is whether Vericel can sustain double-digit product growth and continue expanding margins while bringing new regenerative therapies to market.
Should you buy stock in Vericel right now?
Before you buy stock in Vericel, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vericel wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $398,052!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,181,688!*
Now, it’s worth noting Stock Advisor’s total average return is 892% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 27, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
